Role of Circulating Innate Lymphoid Cells in Allergic Disorders
NCT03069495 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 18
Last updated 2023-08-28
Summary
This study evaluates blood type 2 innate lymphoid cells in participants with mild to moderate asthma and participants with chronic urticaria as compared to healthy adult participants.
Conditions
- Allergy
- Asthma
- Urticaria
Sponsors & Collaborators
-
University of Nebraska
lead OTHER
Principal Investigators
-
Jill A Poole, MD · University of Nebraska
Eligibility
- Min Age
- 19 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-08-21
- Primary Completion
- 2020-02-24
- Completion
- 2020-02-24
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain
NCT01311336 ·Status: UNKNOWN ·Phase: PHASE2
-
T Cell Function in Chronic Idiopathic Urticaria
NCT01425593 ·Status: UNKNOWN
-
Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations
NCT00004694 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
NCT00329381 ·Status: COMPLETED ·Phase: PHASE4
-
Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy
NCT04974970 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Interleukin-2 for Refractory Chronic Spontaneous Urticaria
NCT06924762 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy
NCT04200989 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
NCT00890162 ·Status: COMPLETED ·Phase: PHASE2
-
Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet
NCT05848986 ·Status: UNKNOWN
-
Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
NCT02023151 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
NCT00691873 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
NCT00382148 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
NCT01544348 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Anti-IgE in Chronic Urticaria
NCT00130234 ·Status: COMPLETED ·Phase: PHASE2
-
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
NCT00267501 ·Status: RECRUITING
-
Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy
NCT04148352 ·Status: TERMINATED ·Phase: PHASE2
-
Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995
NCT02082353 ·Status: UNKNOWN
-
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
NCT05528861 ·Status: TERMINATED ·Phase: PHASE2
-
The Metabolomics of Anaphylaxis to Immunotherapy
NCT01666288 ·Status: WITHDRAWN
-
The Effect of Omalizumab on Responses to Cat Allergen Challenge
NCT00604786 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
NCT01292473 ·Status: COMPLETED ·Phase: PHASE3
-
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
NCT02814630 ·Status: COMPLETED ·Phase: NA
-
A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial
NCT00580606 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults
NCT01274429 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma
NCT00242359 ·Status: WITHDRAWN ·Phase: PHASE4